Skip to content

Annexon ANNX Other Non-Current Assets

Other Non-Current Assets at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$2.13B+52.9%
Vor Biopharma logo
Vor BiopharmaVOR
$2.41M+1.6%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$297K-18.9%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$11.24M+108%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$256K0.0%
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
$2.5M+22,627%

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+223%
Enterprise value$718.59M+261%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Reported directly by Annexon in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's other non-current assets?
Annexon (ANNX) reported other non-current assets of $8.72M in Q1 2026.
How has Annexon's other non-current assets changed year-over-year?
Annexon's other non-current assets increased by 64.5% year-over-year, from $5.3M to $8.72M.
What does other non-current assets mean?
This category captures long-term assets that do not fit into standard classifications like property, plant, equipment, or intangible assets. It may include long-term deposits, deferred tax assets, or other miscellaneous non-current investments. It represents the residual value of long-term resources held by the company.